Intraoperative haemostasis with new fibrin surgical sealant (Quixil®) in gynaecological oncology

Summary

We evaluated the effectiveness and safety of Quixil® in gynaecological oncology with a prospective observational study over 11 months in a gynaecological oncology centre. Quixil® was opportunistically used when conventional haemostatic techniques failed, in 35 laparotomies and four laparoscopies. A total of 26 operations were performed for malignant disease and 13 for benign indications. Demographic, intraoperative and postoperative data were collected. Haemostasis was accomplished within 5 min from sealant application. No hypersensitivity reactions were noted. Bowel recovery and postoperative pain were usual. In the laparotomy group, the mean hospital stay was 11 days and mean operating time, 164 min. In the laparoscopy group, the mean hospital stay was 3 days and mean operating time 165 min. In both groups, the incidence of complications and recurrence rates were in line with the expected population rates of these treated patients. We conclude that Quixil® is an efficient, safe and effective haemostatic agent, which has a role to play in gynaecological surgery for benign and malignant disease.

Keywords:

• Quixil
• surgical sealant
• gynaecological oncology
• fibrin
• cancer surgery

Notes

This article is not subject to United States copyright laws.